
    
      Patients with a diagnosis of high risk prostate cancer with a Gleason score of 8 or greater
      are eligible for this trial. The study will enroll 20 subjects in 3 years. This is a single
      arm study and the primary objectives is to assess if a patient can undergo a radical
      prostatectomy after SBRT without a post-operative grade 3 or higher toxicity (according to
      Clavien-Dindo Classification) at 30 days. Secondary objectives are to assess acute toxicity
      and quality of life scores. Exploratory objectives will include analysis of tumor and normal
      biopsied and resected tissue and serum markers and interpretation of interfraction and
      intrafraction MRIs.
    
  